XM does not provide services to residents of the United States of America.
B
B

BayerAG

News

BASF hopes pricing power will boost profit growth later in the year

UPDATE 3-BASF hopes pricing power will boost profit growth later in the year Adds CEO comment in paragraphs 2-4, shares in paragraph 6 By Ludwig Burger FRANKFURT, July 26 (Reuters) - BASF BASFn.DE is banking on regaining pricing power to speed up earnings growth in the second half after the German chemicals group's adjusted profit edged 0.6% higher in the second quarter, with China playing a key role.
B
B
G

Bayer's Monsanto to pay $160 mln to resolve Seattle's PCB contamination lawsuit

Bayer's Monsanto to pay $160 mln to resolve Seattle's PCB contamination lawsuit By Jonathan Stempel July 25 (Reuters) - Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer BAYGn.DE of polluting the city's drainage system and the local Lower Duwamish River with toxic chemicals known as PCBs.
B

Australian judge dismisses lawsuit claiming Bayer weedkiller causes blood cancer

UPDATE 2-Australian judge dismisses lawsuit claiming Bayer weedkiller causes blood cancer Recasts and writes through with comments from judge, Bayer and plaintiffs' lawyers By Peter Hobson and Alasdair Pal CANBERRA, July 25 (Reuters) - An Australian judge on Thursday dismissed a class action lawsuit claiming Bayer's BAYGn.DE Roundup weedkiller can cause a type of blood cancer, a ruling the company said it would seek to leverage in similar cases being fought in the United States.
B

Australian judge dismisses lawsuit claiming Bayer's Roundup weedkiller causes cancer

Australian judge dismisses lawsuit claiming Bayer's Roundup weedkiller causes cancer SYDNEY, July 25 (Reuters) - An Australian judge said on Thursday it was not proven that an ingredient in Bayer's BAYGn.DE Roundup weedkiller increases the risk of cancer in users. Reporting by Alasdair Pal in Sydney Editing by Praveen Menon
B

Roche lifts 2024 profit guidance on strong drug sales

UPDATE 2-Roche lifts 2024 profit guidance on strong drug sales First-half operating profit growth beats analyst estimates Revenue from eye drug Vabysmo nearly doubles, beats estimates Expects close to 10% adjusted profit growth, up vs previous Shares traded near 1-year high earlier on Thursday Adds details on eye drug in paragraphs 5 and 7, details on CEO's strategy in last two paragraphs By Ludwig Burger FRANKFURT, July 25 (Reuters) - Roche ROG.S on Thursday raised its full-year earnings foreca
A
B
R
R
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.